br Acknowledgments br The authors are thankful to rural medical
The authors are thankful to rural medical o cers Dr. Amanpreet Kaur and Dr. Gurdarshan Singh for their valuable help in collection of control samples.
1. Finn R-S, Crown J-P, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.
4. Blaurock-Busch E, Busch Y-M, Friedle A, et al. Comparing the metal concentration in the nails of healthy and cancer patients living in the malwa region of punjab, india with a random european group-a follow up study. Br J Med Med Res. 2015;5:480.
6. Wulaningsih W, Holmberg L, Abeler-Doner L, et al. Associations of C-reactive protein, granulocytes and granulocyte– to-lymphocyte ratio with mortality from breast cancer in non-institutionalized American women. PLoS One. 2016;11.
7. Villaseñor A, Flatt S-W, Marinac C, et al. Postdiagnosis C-reactive protein and breast cancer survivorship: findings from the WHEL study. Cancer Epidemiol Biomark Prev. 2014;23:189–199.
8. Allin K-H, Nordestgaard B-G, Flyger, et al. Elevated pre-treatment levels of CCK-8 C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res. 2011;13:1.
9. Favaro E, Amadori A, Indraccolo S. Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy. Apmis. 2008;116:648–659.
11. Basu S, Harris H, Larsson A, et al. Is there any role for serum cathepsin S and CRP levels on prognostic information in breast cancer? The Swedish mammography cohort. Antioxid Redox Signal. 2015;23:1298–1302.
12. Ridker P-M, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation. 2004;109:1955–1959.
13. Rajeshwar K, Kaul S, Al-Hazzani A, et al. C-reactive protein and nitric oxide levels in ischemic stroke and its subtypes: correlation with clinical outcome. Inflammation. 2012;35:978–984.
14. Schmid M, Schneitter A, Hinterberger S, et al. Association of elevated C-reactive protein levels with an impaired prognosis in patients with surgically treated endometrial cancer. Obstet Gynecol. 2007;110:1231–1236.
16. Allin K-H, Bojesen S-E, Nordestgaard B-G. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27:2217–2224.
17. Roxburgh C-S, McMillan D-C. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6:149–163.
19. Takeuchi H, Kawanaka H, Fukuyama S, et al. Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer. PLoS One. 2017;12:1–5.
20. Al Murri A-M, Wilson C, Lannigan A, et al. Evaluation of the relationship between the systemic inflammatory re-sponse and cancer-specific survival in patients with primary operable breast cancer. Br J Cancer. 2007;96:891–895.
21. Pasanisi P, Venturelli E E, Morelli D. Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. Cancer Epidemiol Biomark Prev. 2008;17:1719–1722.
22. Pierce B-L, Ballard-Barbash R, Bernstein L. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27:3437–3444.
23. Chang C-C, Sun C-F, Pai H-J, et al. Preoperative serum C-reactive protein and gastric cancer; clinical-pathological correlation and prognostic significance. Chang Gung Med J. 2010;33:301–312.
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/genrep